Circulating thrombospondin-2 in patients with moderate-to-severe chronic heart failure due to coronary artery disease |
| |
Authors: | Alexander E Berezin Alexander A Kremzer Tatayna A Samura |
| |
Affiliation: | 1.Department of Internal Medicine2.Department of Clinical Pharmacology, State Medical University, Zaporozhye 69035, Ukraine. |
| |
Abstract: | Chronic heart failure (CHF) remains a leading cause of morbidity and mortality. In the current study, we aimed to evaluate the predictive value of circulating thrombospondin-2 (TSP-2) for cumulative survival in patients with ischemic CHF due to coronary artery disease (CAD). The results showed that during a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repeatedly. The median circulating levels of TSP-2 in patients who survived and those who died were 0.63 ng/mL (95%CI = 0.55-0.64 ng/mL) and 1.03 ng/mL (95% CI = 0.97-1.07 ng/mL) (P<0.001). Circulating TSP-2 independently predicted all-cause mortality (OR = 1.27; 95%CI = 1.08–1.59; P = 0.002), CHF-related death (OR = 1.16; 95%CI = 1.02–1.50; P<0.001), and also CHF-related rehospitalization (OR = 1.12; 95%CI = 1.07–1.25; P<0.001). In conclusion, among CAD patients with symptomatic CHF, increased circulating TSP-2 is correlated with increased 3-year CHF-related death, all-cause mortality, and risk for recurrent hospitalization. |
| |
Keywords: | thrombospondin-2 chronic heart failure survival hospitalization prognosis |
|
| 点击此处可从《Journal of biomedical research》浏览原始摘要信息 |
|
点击此处可从《Journal of biomedical research》下载全文 |